A Novel Strategy Targeting Myeloid Cells and T Cells in Renal Cell Carcinoma

Attend this 29-minute webinar to explore groundbreaking research on overcoming immune checkpoint blockade resistance in renal cell carcinoma through dual targeting of myeloid cells and T cells. Learn about blood-based biomarker analysis that revealed elevated transcription factors in myeloid cells among non-responders to nivolumab/ipilimumab immunotherapy, suggesting that T cell-focused approaches may inadvertently activate alternative immune resistance pathways. Discover how a novel CpG-STAT3 inhibitor strategy targeting these transcription factors in myeloid cells, when combined with immune checkpoint blockade, demonstrated improved therapeutic responses in preclinical studies. Examine the potential of this oligonucleotide-based approach to disrupt tolerogenic signaling, restore immune cell activity, and enhance sensitivity to immune checkpoint inhibitors and T cell-based immunotherapies in genitourinary cancers. Gain insights into translational research methodology for developing novel therapeutic strategies that could advance from bench to bedside, presented by Dr. Marice Alcantara, a PhD researcher specializing in immuno-oncology at City of Hope National Medical Center with extensive experience in both clinical trials and preclinical drug development for kidney cancer.